Rakesh Uppal, chief executive of the Barts Life Sciences Cluster, says that an ambitious life sciences strategy for London demands equally ambitious partnerships.

I welcome the publication of London’s Life Sciences Strategy, ambitious, but grounded in where London has fallen short.

The strategy rightly identifies the challenge: creating the conditions for the NHS, academia and industry to work together more effectively, generating evidence, accelerating adoption and ensuring innovation reaches the communities that stand to benefit most.

At a recent Association of British HealthTech Industries (ABHI), Barts Health roundtable, leaders from across the ecosystem echoed these concerns. The NHS, they argued, is rich in innovation but poor in routes to adoption. Technologies stall in pilots not because they lack value, but because the system lacks the structures to industrialise innovation. As one participant put it, “The challenge is not innovation. It is industrialising innovation into the NHS.”

The London Life Sciences Strategy gets this right. But strategies do not deliver themselves. What matters now is execution, which depends on something London has historically lacked: places where industry and the NHS can work side by side, aligned around real clinical need, real‑world evidence and clear adoption pathways.

Globally significant

This is precisely the opportunity we are seeking to realise through the Barts Life Sciences Cluster in Whitechapel. Anchored by The Royal London Hospital – part of Barts Health NHS Trust – and its academic partners, the Cluster is being developed as a globally significant centre for applied life sciences, bringing together clinicians, researchers, entrepreneurs and industry around real-world healthcare challenges. Located in one of Europe’s most diverse communities, it offers a unique environment in which innovation can be developed, evaluated and adopted at scale.

More than £800 million has already been committed to developing the Cluster, with the ambition not only to accelerate the translation of innovation into healthcare but also to create new jobs and opportunities in one of the most deprived areas of the country, ensuring that London’s life sciences growth is genuinely inclusive.

This is the kind of environment the London Life Sciences Strategy envisions through its new Health Innovation Zone: a living clinical ecosystem where discovery, evidence, adoption and investment come together.

The strategy is bold. But its impact will depend on whether industry and the NHS choose to work not in parallel, but in partnership. If they do, London can finally move from potential to impact, from pilots to system‑wide adoption, and from world‑class science to world‑leading outcomes. The benefits would be felt across the NHS, industry, local communities and, above all, by the patients we serve.

The challenge now is not defining the opportunity. It is executing it.